Abeclib®
Oral Tablet

Brand Name:
Abeclib®150
Generic Name:
Abemaciclib
Strength:
150mg
Description:
Oral Tablet
Pack Size:
30's

Brand Name:
Abeclib®200
Generic Name:
Abemaciclib
Strength:
200mg
Description:
Oral Tablet
Pack Size:
14's
* Storage Conditions: Keep away from the reach of children. Store below 30° C temperature. Keep away from light and wet place.
FDA Approved Indications of Abeclib
Abeclib™ is a kinase inhibitor indicated:
- As monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
- In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
- In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20% as determined by an FDA approved test.